PC
RIGL icon

Polar Capital’s Rigel Pharmaceuticals RIGL Stock Holding History

Polar Capital’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-51,782
Closed -$2.01M – 284
2014
Q1 		$2.01M Buy
+51,782
New +$1.85M 0.05% 220

Other funds holding RIGL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Polar Capital's RIGL Position: Q2 2014 in Review

Polar Capital sold out of Rigel Pharmaceuticals (RIGL) in Q2 2014, closing a stake of 51,782 shares — an estimated $2.01M sold.

Polar Capital first reported a position in RIGL in Q1 2014 and held it in 1 quarter. The position peaked at $2.01M in Q1 2014. 103 funds tracked by Wall St. Rank hold RIGL as of Q2 2014.

  • Polar Capital reported no remaining Rigel Pharmaceuticals position as of Q2 2014 after selling out during the quarter.
  • Polar Capital sold 51,782 Rigel Pharmaceuticals shares in Q2 2014, an estimated $2.01M.
  • Polar Capital first reported a position in Rigel Pharmaceuticals in Q1 2014 and held it in 1 quarter.
  • Polar Capital's Rigel Pharmaceuticals position peaked at $2.01M in Q1 2014.
  • 103 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2014.

Based on Polar Capital's 13F filing for Q2 2014, filed 12 Aug 2014.